These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35122592)

  • 21. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
    Corsetti M; Whorwell P
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):285-292. PubMed ID: 28276811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.
    Fragkos KC
    Clin Exp Gastroenterol; 2017; 10():229-240. PubMed ID: 28989282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
    Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
    Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ▼ Eluxadoline for IBS-D.
    Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
    Lacy BE; Gagnon-Sanschagrin P; Heimanson Z; Bungay R; Bellefleur R; Guérin A; Bumpass B; Borroto D; Joseph G; Dashputre AA
    Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eluxadoline: First Global Approval.
    Garnock-Jones KP
    Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
    Chey WD; Dove LS; Andrae DA; Covington PS
    Aliment Pharmacol Ther; 2017 May; 45(10):1319-1328. PubMed ID: 28326568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J; Vanuytsel T; Corsetti M
    Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
    Vera I; Júdez FJ
    Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
    Chhaparia A; Hammami MB; Vareedayah A; Schroeder K
    Del Med J; 2017 Mar; 89(3):90-92. PubMed ID: 29894043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New treatment options for irritable bowel syndrome with predominant diarrhea.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Bile Acid Diarrhea in Patients With Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life.
    BouSaba J; Sannaa W; McKinzie S; Vijayvargiya P; Chedid V; Wang XJ; Atieh J; Zheng T; Brandler J; Taylor AL; Busciglio I; Harmsen WS; Camilleri M
    Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2083-2090.e1. PubMed ID: 34871814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.
    Barshop K; Staller K
    Ther Adv Chronic Dis; 2017 Nov; 8(11):153-160. PubMed ID: 29090081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.
    Lacy BE; Harris LA; Chang L; Lucak S; Gutman C; Dove LS; Covington PS; Lembo A
    Therap Adv Gastroenterol; 2019; 12():1756284819841290. PubMed ID: 31019552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of Bile Acid Metabolism in Pediatric Diarrhea Predominant Irritable Bowel Syndrome and Healthy Controls.
    Beinvogl BC; Manini ML; Camilleri M; Donato LJ; Harmsen WS; Absah I; Burch E; Schechter NL; Nurko S
    J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):859-865. PubMed ID: 33976086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.
    Lacy BE
    Aliment Pharmacol Ther; 2018 Oct; 48(8):817-830. PubMed ID: 30194692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
    Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
    Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.